Lista de obras -

A Novel Interplay between Rap1 and PKA Regulates Induction of Angiogenesis in Prostate Cancer ⬇️

artículo científico publicado el 15 de noviembre de 2012

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer ⬇️

artículo científico publicado el 1 de febrero de 2012

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

scientific article published on 28 November 2018

A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis.

artículo científico publicado en 2009

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

artículo científico publicado en 2014

A time to test, a time to treat ⬇️

artículo científico publicado el 1 de abril de 2012

Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents ⬇️

artículo científico publicado el 1 de enero de 2013

Activation of RAS family members confers resistance to ROS1 targeting drugs.

artículo científico publicado en 2015

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

artículo científico publicado en 2016

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

artículo científico publicado en 2015

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed ⬇️

artículo científico publicado el 1 de abril de 2011

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 6 de agosto de 2013

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer ⬇️

artículo científico publicado el 26 de enero de 2012

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

artículo científico publicado en 2014

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer ⬇️

artículo científico publicado el 20 de diciembre de 2012

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

scientific article published on 11 December 2018

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience

artículo científico publicado en 2016

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

artículo científico publicado en 2011

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR ⬇️

artículo científico publicado el 1 de septiembre de 2013

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

artículo científico publicado en 2012

Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides

artículo científico publicado en 2003

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2012

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

artículo científico

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status

artículo científico publicado en 2016

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

artículo científico publicado en 2016

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

artículo científico publicado en 2012

Molecular Pathways: ROS1 Fusion Proteins in Cancer ⬇️

artículo científico publicado el 29 de mayo de 2013

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

artículo científico publicado en 2015

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy

artículo científico publicado en 2013

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

scientific article published on 25 January 2010

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions.

scientific article published on 29 December 2016

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer ⬇️

artículo científico publicado el 26 de enero de 2012

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

artículo científico publicado en 2010

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

artículo científico publicado en 2014

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

artículo científico publicado en 2015

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

artículo científico publicado en 2014

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

artículo científico publicado en 2010

Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents

artículo científico

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

artículo científico publicado en 2018

Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.

artículo científico publicado en 2018

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

artículo científico publicado en 2013

Rociletinib in EGFR-mutated non-small-cell lung cancer

artículo científico publicado en 2015

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

artículo científico publicado en 2014

TRKing down an old oncogene in a new era of targeted therapy

artículo científico publicado en 2015

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

artículo científico publicado en 2013

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor

artículo científico publicado en 2013

Targeting ALK, ROS1, and BRAF Kinases ⬇️

artículo científico publicado el 1 de diciembre de 2012

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

artículo científico publicado en 2017

Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

artículo científico publicado en 2020

The evolution of tumor classification: a role for genomics?

artículo científico publicado en 2013

The minority report: targeting the rare oncogenes in NSCLC

artículo científico publicado en 2014

Treating ALK-positive lung cancer—early successes and future challenges ⬇️

artículo científico publicado el 3 de abril de 2012

Lista de obras de

A Novel Interplay between Rap1 and PKA Regulates Induction of Angiogenesis in Prostate Cancer ⬇️

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer ⬇️

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis.

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer

A time to test, a time to treat ⬇️

Acquired Resistance to Targeted Therapies in Advanced Non-Small Cell Lung Cancer: New Strategies and New Agents ⬇️

Activation of RAS family members confers resistance to ROS1 targeting drugs.

An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed ⬇️

Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer ⬇️

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization–positive nonsmall cell lung cancer ⬇️

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Diagnostic assays for identification of anaplastic lymphoma kinase‐positive non–small cell lung cancer ⬇️

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Do More With Less: Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for Molecular and Ancillary Testing: The University of Colorado Experience

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Erlotinib Response in an NSCLC Patient with a Novel Compound G719D+L861R Mutation in EGFR ⬇️

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer ⬇️

Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Molecular Pathways: ROS1 Fusion Proteins in Cancer ⬇️

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014

Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

Non-malignant respiratory epithelial cells preferentially proliferate from resected non-small cell lung cancer specimens cultured under conditionally reprogrammed conditions.

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer ⬇️

Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

Re-examination of maintenance therapy in non-small cell lung cancer with the advent of new anti-cancer agents

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

Rociletinib in EGFR-mutated non-small-cell lung cancer

Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib

TRKing down an old oncogene in a new era of targeted therapy

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor

Targeting ALK, ROS1, and BRAF Kinases ⬇️

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes

The evolution of tumor classification: a role for genomics?

The minority report: targeting the rare oncogenes in NSCLC

Treating ALK-positive lung cancer—early successes and future challenges ⬇️